This article has Open Peer Review reports available.
Vitamin B12 deficiency with combined hematological and neuropsychiatric derangements: a case report
© Rannelli et al.; licensee BioMed Central Ltd. 2014
Received: 19 April 2014
Accepted: 3 July 2014
Published: 15 August 2014
Although vitamin B12 deficiency is a well-known cause of hematological and neuropsychiatric illness, the presentation of combined severe pancytopenia, demyelination and prominent psychiatric impairment is rare.
We present a case of a previously healthy 55-year-old East African man with severe vitamin B12 deficiency (serum vitamin B12 22pmol/L) secondary to pernicious anemia. He had a severe hypoproliferative megaloblastic anemia with hemolysis (hemoglobin 61g/L, mean corpuscular volume 99fL, reticulocytes 0.8%, haptoglobin undetectable), leukopenia (2.7×109/L), thrombocytopenia (96×109/L), ataxia with central demyelination, and megaloblastic madness. The patient’s anemia, myelopathy and psychiatric condition responded well to parenteral vitamin B12 replacement therapy, with significant improvement seen within weeks.
Hematological manifestations of vitamin B12 deficiency are typically inversely correlated with the presence and severity of neuropsychiatric impairment. Although uncommon, a presentation with severe hematological and neuropsychiatric disease can occur, as illustrated by this case. Its presence may help guide diagnosis as well as provide clinically important prognostic information.
Vitamin B12 is essential for normal blood synthesis and neurological function. Vitamin B12 deficiency may cause megaloblastic anemia, subacute combined degeneration of the cord and psychiatric illness (“megaloblastic madness”). Notably, the degree of bone marrow suppression is typically inversely related to both the presence and severity of neurological involvement. As such, the coexistence of significant anemia and neurological deficits is thought to be rare. We describe an unusual case of a patient with severe vitamin B12 deficiency together with profound hematological derangements and florid neuropsychiatric impairment.
A 55-year-old man of East African descent presented to our community hospital with a history of repeated falls, postural dizziness, progressive fatigue, generalized weakness and 30-lb weight loss over the course of three to six months. He is a vegetarian. His collateral history obtained from family members confirmed a significant behavioral change over the past year, during which they observed irritability and emotional lability, as well as difficulty with self-care, grooming and personal hygiene. He was high-functioning before the onset of his present illness. During a review of systems, he denied any sensory deficits, visual impairment or taste perversion, and he also denied any history of bleeding, bruising or recent infection. His past medical history was unremarkable. He was not taking any medications at the time of presentation. The patient denied smoking, alcohol consumption or illicit drug use. He had no significant family history of any illness.
The initial examination in the emergency department revealed a poorly groomed, disheveled thin man who appeared older than his stated age. He was irritable, paranoid, delusional and highly circumstantial and had grandiose thoughts and impaired insight. He denied any hallucinations. The patient’s blood pressure was 96/50mmHg without postural change, his pulse was 92 beats/min and his respiratory rate was 16 breaths/min. He was afebrile. His neurological examination was limited because he was uncooperative, but he was observed to have an unstable, wide-based, ataxic gait as well as difficulty in performing rapid, alternating hand movements. His proprioception, vibration sense and light-touch sensory modalities appeared grossly preserved. His reflexes were symmetric and normal. His cardiovascular, respiratory, abdominal and dermatological examination results were unremarkable. Of note, he did not have evidence of splenomegaly, oral ulcers, nail changes or vitiligo. The patient was subsequently admitted to the hospital for further evaluation.
A complete blood count revealed hemoglobin 61g/L (mean corpuscular volume 99fL), thrombocytopenia 96×109 and leukopenia 2.7×109. The patient’s reticulocytes were decreased at 14×109/L (0.8%). A peripheral blood smear demonstrated hypersegmented neutrophils and schistocytes. His serum vitamin B12 level was decreased at 22pmol/L (reference range 155pmol/L to 700pmol/L), his serum haptoglobin was undetectable and his serum lactate dehydrogenase was elevated at 1135U/L. The patient’s iron studies, folate, thyroid-stimulating hormone, liver enzymes, fibrinogen, serum protein electrophoresis, anti–tissue transglutaminase antibodies, hemoglobin A1c, coagulation panel, electrolytes and serum creatinine were all within normal limits. Viral studies for parvovirus B19, cytomegalovirus and human immunodeficiency virus were unremarkable. However, anti–intrinsic factor antibodies were detected. His blood type was B+. Of note, all blood work was performed prior to commencing any medical treatment or blood transfusions.
The diagnosis of severe vitamin B12 deficiency secondary to pernicious anemia was established on the basis of an unequivocally low serum vitamin B12 level and the presence of anti–intrinsic factor antibodies. The patient’s long-standing vegetarian diet may also have been a contributor to his vitamin B12 deficiency. Other causes of pancytopenia which may be characterized by a hypoproliferative, megaloblastic, macrocytic anemia—such as folate deficiency, hypothyroidism, viral illness and exposure to potential offending medications—were ruled out. The patient’s formal neurological and psychiatric evaluations were also consistent with central demyelinating disease and megaloblastic madness with prominent depressive features, after potential confounding metabolic and anatomical causes were excluded.
Because of the profound symptomatic anemia at presentation, the patient was initially given a transfusion of 2U of packed red blood cells upon admission. He was then initiated on daily subcutaneous injections of vitamin B12 at 1000μg for one week, followed by weekly injections for the next four weeks, and he was subsequently prescribed monthly injections to be continued indefinitely. Within the first week of treatment, the patient’s pancytopenia had nearly resolved. His neuropsychiatric symptoms and cognition had also improved significantly by the time of hospital discharge. At follow-up three months later, the patient’s neuropsychiatric impairment had completely resolved. He denied any psychiatric disturbance, demonstrated a normal gait and had normal reflexes upon follow-up.
Vitamin B12 deficiency is common, with an estimated prevalence of 15% in patients >60 years of age. Although most cases are clinically subtle, vitamin B12 deficiency may sometimes present with florid disease [1, 2]. When present, symptoms and signs can be broadly classified into hematological and neurological categories. Classically, vitamin B12 deficiency may give rise to megaloblastic anemia and sub-acute combined degeneration of the spinal cord with demyelination of the dorsal column, resulting in both motor and sensory deficits. Less commonly, hemolysis and pancytopenia may be detected in the blood work, and neurological sequelae of optic nerve atrophy, autonomic nervous system dysfunction, peripheral neuropathy, as well as psychiatric complications of emotional lability, mania, paranoia, delusions, amnesia and psychosis, may also be present .
Notably, the degree of megaloblastic anemia in a patient with vitamin B12 deficiency is inversely correlated with the presence and severity of neuropsychiatric symptoms at the time of presentation [3–6]. Severe anemia is rarely accompanied by any neurological symptoms or signs . Likewise, hematocrit and mean corpuscular volume are commonly normal in patients with neuropsychiatric abnormalities [3, 5]. The underlying reason for this relationship remains unclear. However, it is postulated that the mechanism responsible for the neurological dysfunction associated with vitamin B12 deficiency is altogether different from those responsible for the hematological sequelae. Vitamin B12 acts as a coenzyme for L-methylmalonyl-coenzyme A mutase and methionine synthetase. Accordingly, enzymatic defects resulting from vitamin B12 deficiency lead to accumulation of methylmalonic acid and homocysteine, which appear to be proportionally related to the severity of the associated neurological and psychiatric abnormalities . In contrast, inadequate vitamin B12 results in ineffective DNA synthesis and impaired erythropoiesis, which account for the majority of the associated hematological derangements . The underlying mechanisms responsible for the resulting megaloblastic anemia appear to be altogether different from the processes that produce the neurological sequelae of vitamin B12 deficiency.
Myelopathy and peripheral neuropathy collectively account for the vast majority of neurological dysfunction , with mental impairment representing approximately 15% of cases [4, 6]. Among patients with neurological disease, anemia and macrocytosis are the most common hematological derangements detected, and, when they are present, anemia and macrocytosis are typically minor and subtle [4, 6]. In contrast, pancytopenia, severe anemia (that is, <60g/L), hemolysis, leukopenia and thrombocytopenia are all documented to be rare [2, 3, 5].
The presence of anemia also carries important prognostic significance. Anemia detected at baseline is inversely related to the severity of neurological impairment at diagnosis. Even after adjusting for differences in age, sex, mean corpuscular volume, serum vitamin B12 level and disease duration, a lower hematocrit level remains an independent predictor of worse neurological disease . It appears that the presence of anemia at baseline also favors a better neurological response to treatment and a more favorable long-term recovery .
Pernicious anemia can present with severe hematologic and neuropsychiatric conditions concurrently, contrary to stated dogma. Transient, self-limited neurological exacerbations may sometimes occur during the first few weeks of treatment. However, appropriate therapy can lead to complete recovery in up to two-thirds of patients treated [2, 3].
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We would like to thank Dr Hasiba Imam and Dr Rosalyn McAuley, residents in internal medicine and psychiatry, who were involved quite closely with the patient’s care and documentation of his course in the hospital.
- Andrès E, Loukili NH, Noel E, Kaltenbach G, Ben Abdelgheni M, Perrin AE, Noblet-Dick M, Maloisel F, Schlienger JL, Blicklé JF: Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004, 171: 251-259. 10.1503/cmaj.1031155.View ArticlePubMedPubMed CentralGoogle Scholar
- Andrès E, Affenberger S, Zimmer J, Vinzio S, Grosu D, Pistol G, Maloisel F, Weitten T, Kaltenbach G, Blicklé JF: Current hematological findings in cobalamin deficiency: a study of 201 consecutive patients with documented cobalamin deficiency. Clin Lab Haematol. 2006, 28: 50-56. 10.1111/j.1365-2257.2006.00755.x.View ArticlePubMedGoogle Scholar
- Stabler SP: Vitamin B12 deficiency. N Engl J Med. 2013, 368: 149-160. 10.1056/NEJMcp1113996.View ArticlePubMedGoogle Scholar
- Lindenbaum J, Healton EB, Savage DG, Brust JCM, Garrett TJ, Podell ER, Marcell PD, Stabler SP, Allen RH: Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988, 318: 1720-1728. 10.1056/NEJM198806303182604.View ArticlePubMedGoogle Scholar
- Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH: Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994, 60: 2-11.PubMedGoogle Scholar
- Healton EB, Savage DG, Brust JCM, Garrett TJ, Lindenbaum J: Neurologic aspects of cobalamin deficiency. Medicine. 1991, 70: 229-245.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.